Department of Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Fooyin University College of Nursing, Kaohsiung, Taiwan.
J Altern Complement Med. 2021 Jul;27(7):579-587. doi: 10.1089/acm.2020.0524. Epub 2021 Apr 27.
To investigate the efficacy of laser acupuncture (LA) therapy in patients with dry eye disease (DED). A two-center randomized controlled trial. The Department of Ophthalmology, Chinese Medicine at the Kaohsiung Chang Gung Memorial Hospital, and the Sunming Eye Clinic in South Taiwan. Fifty-nine participants ages 20 to 65 years were enrolled and randomly assigned to the experimental group (LA plus conventional treatment) or the sham control group (LA without laser output plus conventional treatment). Subjects underwent LA treatment three times a week for 12 weeks. The subjects in the experimental group sequentially received 0.375 J of energy at each of the following acupoints: BL2, TE23, ST2, LI4, ST36, and GB37. Subjects in the control group received a sham LA treatment, without any laser output. The primary outcome measure was ocular surface disease index (OSDI). The secondary outcome measures included tear film breakup time (TFBUT), Schirmer-I test finding, and visual analog scale (VAS) score. At 4 and 12 weeks after the first visit, the experimental group showed significant improvement of dry eye symptoms as measured by OSDI, TFBUT, Shirmer-I test, and VAS. Compared with the control group, the OSDI (7.23, = 0.001) and TFBUT (-1.78, = 0.001) significantly improved in the experimental group at 12 weeks of treatment. LA improved the symptoms and tear stability related to DED in conjunction with conventional treatment. The authors suggest that LA be considered a complementary therapy for DED when conventional treatment does not provide satisfactory effects. ClinicalTrials.gov Identifier NCT03204903.
探究激光针灸(LA)疗法治疗干眼症(DED)的疗效。一项两中心随机对照试验。台湾南部新明眼科诊所与高雄长庚纪念医院中医部眼科。共纳入 59 名 20 至 65 岁的参与者,并随机分为实验组(LA 联合常规治疗)和 sham 对照组(LA 无激光输出联合常规治疗)。受试者每周接受 LA 治疗 3 次,共 12 周。实验组受试者依次在以下穴位接受 0.375 J 的能量:BL2、TE23、ST2、LI4、ST36 和 GB37。对照组受试者接受 sham LA 治疗,无任何激光输出。主要结局指标为眼表疾病指数(OSDI)。次要结局指标包括泪膜破裂时间(TFBUT)、Schirmer-I 试验结果和视觉模拟评分(VAS)。在首次就诊后 4 周和 12 周,实验组的干眼症状(OSDI、TFBUT、Shirmer-I 试验和 VAS)均有显著改善。与对照组相比,实验组在治疗 12 周时 OSDI(7.23, = 0.001)和 TFBUT(-1.78, = 0.001)显著改善。LA 与常规治疗联合改善了与 DED 相关的症状和泪液稳定性。作者建议,当常规治疗效果不佳时,可考虑将 LA 作为 DED 的补充治疗方法。ClinicalTrials.gov 标识符 NCT03204903。